Faculty Sponsor

Jana Stedman, PA-C

College

Nursing

Department/Program

Physician Assistant Masters Program

Presentation Type

Poster Presentation

Symposium Date

Summer 7-24-2024

Abstract

Objective: Approximately 20% of patients with a history an ischemic stroke will have a recurrent stroke, which can be very debilitating events. This research paper aims to determine the effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors) as secondary prevention to reduce the incidence of ischemic strokes. Methods:Google Scholar and Summon were used to research articles. Academic studies published within the past 5 years were selected. Filters placed on the searching platforms were ‘peer reviewed journals’, ‘full text available’, ‘meta-analysis’, ‘systemic review’, ‘randomized control studies’, and ‘retrospective analysis’. Results: PCSK9 inhibitors decrease the incidence of recurrent ischemic strokes when used in combination with statin therapy or monotherapy compared to statin monotherapy and no therapy respectively. The use of PCSK9 inhibitors had no correlation with the incidence of hemorrhagic strokes or neurocognitive events. Conclusion: PCSK9 inhibitors are an effective therapy for secondary prevention of ischemic strokes in patients with statin tolerance or hyperlipidemia resistant to statin therapy without increasing the risk of hemorrhagic strokes or neurocognitive events.

Keywords: PCSK9 inhibitors, statin, ischemic stroke, hemorrhagic stroke, neurocognitive effects

Download

Share

COinS